BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17028293)

  • 1. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?
    Henke M; Mattern D; Pepe M; Bézay C; Weissenberger C; Werner M; Pajonk F
    J Clin Oncol; 2006 Oct; 24(29):4708-13. PubMed ID: 17028293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?
    Clavo B
    J Clin Oncol; 2007 Apr; 25(11):1447-8; author reply 1448. PubMed ID: 17416869
    [No Abstract]   [Full Text] [Related]  

  • 3. Heat shock protein 70, erythropoietin, and cancer.
    Sizer KC
    J Clin Oncol; 2007 Sep; 25(27):4326; author reply 4326-7. PubMed ID: 17878490
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.
    Henke M; Laszig R; Rübe C; Schäfer U; Haase KD; Schilcher B; Mose S; Beer KT; Burger U; Dougherty C; Frommhold H
    Lancet; 2003 Oct; 362(9392):1255-60. PubMed ID: 14575968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erythropoietin in patients with head and neck carcinomas?].
    Schipper J; Henke M
    Laryngorhinootologie; 2004 May; 83(5):292-7. PubMed ID: 15143446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
    J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03).
    Machtay M; Pajak TF; Suntharalingam M; Shenouda G; Hershock D; Stripp DC; Cmelak AJ; Schulsinger A; Fu KK;
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1008-17. PubMed ID: 17716826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
    Hoskin PJ; Robinson M; Slevin N; Morgan D; Harrington K; Gaffney C
    J Clin Oncol; 2009 Dec; 27(34):5751-6. PubMed ID: 19884550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of tumor expression of erythropoietin receptors and erythropoietin on clinical outcome of esophageal cancer patients treated with chemoradiation.
    Rades D; Golke H; Schild SE; Kilic E
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):152-9. PubMed ID: 17967510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
    Wright JR; Ung YC; Julian JA; Pritchard KI; Whelan TJ; Smith C; Szechtman B; Roa W; Mulroy L; Rudinskas L; Gagnon B; Okawara GS; Levine MN
    J Clin Oncol; 2007 Mar; 25(9):1027-32. PubMed ID: 17312332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo.
    Sasaki Y; Kjellén E; Mineta H; Wennerberg J; Ekblad L
    Acta Oncol; 2009; 48(7):1062-9. PubMed ID: 19412811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas.
    Hoogsteen IJ; Peeters WJ; Marres HA; Rijken PF; van den Hoogen FJ; van der Kogel AJ; Kaanders JH
    Radiother Oncol; 2005 Aug; 76(2):213-8. PubMed ID: 16112214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of the microenvironment of head and neck cancers on tumor progression].
    Lukits J
    Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer.
    Saintigny P; Besse B; Callard P; Vergnaud AC; Czernichow S; Colombat M; Girard P; Validire P; Breau JL; Bernaudin JF; Soria JC
    Clin Cancer Res; 2007 Aug; 13(16):4825-31. PubMed ID: 17699861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anemia in head and neck cancers].
    Azria D; Zouhair A; Serre A; Lemanski C; Schneider M; Ozsahin M; Dubois JB; Lartigau E;
    Bull Cancer; 2005 May; 92(5):445-51. PubMed ID: 15932808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of erythropoetin receptor expression in tumour tissue for the clinical course of breast cancer.
    Volgger B; Kurz K; Zöschg K; Theurl I; Ciresa-König A; Marth C; Weiss G
    Anticancer Res; 2010 Sep; 30(9):3721-6. PubMed ID: 20944160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of telomerase expression in peripheral blood mononuclear cells of head and neck cancer patients.
    Lee BJ; Wang SG; Choi JS; Lee JC; Goh EK; Kim MG
    Am J Clin Oncol; 2006 Apr; 29(2):163-7. PubMed ID: 16601436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.
    Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J
    J Clin Oncol; 2009 Apr; 27(12):1992-8. PubMed ID: 19289615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.